Abstracts tagged "synovial fluid and tumor necrosis factor (TNF)"

Abstract Number: 1117 • 2016 ACR/ARHP Annual Meeting
EGCG Down-Regulates TNF-α-Induced Mcl-1 Expression By Modulating Mule/Huwe1, β-TrCP, and USP9X Ubiquitin/De-Ubiquitin Ligases in Rheumatoid Arthritis Synovial Fibroblasts
Nahid Akhtar¹, Sadiq Umar², David Fox³ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA, ²Department of Pharmaceutical Science, Washington State University, College of Pharmacy, Spokane, WA, ³Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI
Background/Purpose: Myeloid cell leukemia (Mcl-1) phosphorylation at Ser64 position (p-Mcl-1Ser64) has been shown to enhance Mcl-1’s stability and resistance to proteasomal degradation. However, the…
Abstract Number: 2557 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor (TNF) Sensitizes Rheumatoid Synovial Fibroblasts to TRPA1-Mediated Calcium Flux, Anti-Proliferation and Cell Death
Torsten Lowin¹, Rainer Straub² and Georg Pongratz³, ¹Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany, ²Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany, ³Rheumatology - Hiller Research Center Rheumatology, University Hospital Duesseldorf, Duesseldorf, Germany
Background/Purpose: In rheumatoid arthritis (RA), synovial fibroblasts (SF) are one main contributor of joint destruction since they resist apoptosis and secrete pro-inflammatory cytokines and matrix…
Abstract Number: 2447 • 2014 ACR/ARHP Annual Meeting
The Role of TET3-Mediated DNA Demethylation By Pro-Inflammatory Cytokines in Rheumatoid Arthritis
Kazuhisa Nakano¹, Kunihiro Yamaoka¹, Akira Kurozumi², Akio Kawabe², Kaoru Yamagata² and Yoshiya Tanaka³, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose In the pathogenesis of Rheumatoid arthritis (RA) RA fibroblast-like synoviocytes (RA FLS) exhibit a unique aggressive phenotype that contributes to the cytokine milieu and…
Abstract Number: 1042 • 2014 ACR/ARHP Annual Meeting
IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts
Christelle Darrieutort-Laffite^1,2, Marie Astrid Boutet¹, Mathias Chatelais¹, Regis Brion³, Frederic Blanchard¹, Dominique Heymann³ and Benoit Le Goff^1,2, ¹Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, INSERM, UMR 957, Nantes, France, ²Rheumatology, Nantes University Hospital, Nantes, France, ³Laboratoire de Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Nantes, INSERM, UMR 957, Nantes, France
Background/Purpose Macrophages and synovial fibroblasts (SF) are two major cells implicated in the pathogenesis of rheumatoid arthritis (RA). They can interact in the synovial micro-environment…
Abstract Number: 1001 • 2014 ACR/ARHP Annual Meeting
Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1
Satoshi Yamasaki and Eiji Sugiyama, Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan
Background/Purpose: There is evidence of osteoclast activation in the inflamed joints of patients with rheumatoid arthritis (RA). Studies that focus on osteoblasts are not sufficient…
Abstract Number: 1856 • 2013 ACR/ARHP Annual Meeting
Potentiating Effects Of IL-17A, IL-17AF, IL-17F In Combination With TNF But Not With IL-1beta In Human Primary Fibroblast-Like Synoviocytes From Rheumatoid Arthritis Patients
Christine Huppertz¹, Marija Curcic Djuric¹, Robert Hennze¹, Friedrich Raulf¹, Frank Kolbinger¹, Anis Mir¹ and David Lee², ¹Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland, ²Novartis Pharma AG, Basel, Switzerland
Background/Purpose: The pro-inflammatory cytokine interleukin-17A (IL-17A) activates fibroblast-like synoviocytes (FLS) and other mesenchymal cells via the IL-17RA/RC receptor. FLS are a major source of inflammatory…
Abstract Number: 951 • 2013 ACR/ARHP Annual Meeting
The Anti-IL-17A Monoclonal Antibody Secukinumab (AIN457) Inhibits Pro-Inflammatory Mediator Release From Human Primary Synoviocytes Costimulated With IL-17 and TNF
Christine Huppertz, Marija Curcic Djuric, Robert Hennze and Frank Kolbinger, Autoimmunity, Transplantation and Inflammatory Disease, Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, SWITZERLAND, Basel, Switzerland
Background/Purpose: Fibroblast-like synoviocytes (FLS) are targets of the pro-inflammatory IL-17 cytokines and a major source of inflammatory mediators in the inflamed synovium in rheumatoid arthritis…
Abstract Number: 428 • 2012 ACR/ARHP Annual Meeting
TNFα Modulates the Expression of Circadian Clock Gene, Per2, Via D-Box Motif in the Promoter Region in Rheumatoid Synovial Cells
Kohsuke Yoshida¹, Akira Hashiramoto², Takaichi Okano³, Nao Shibanuma⁴ and Shunichi Shiozawa⁵, ¹Hyogo Prefectural Rehabilitation Center at Nishi-harima, Tatsuno, Japan, ²Department of Internal Medicine, Kobe University Graduate School of Medicine / The Center for Rheumatic Diseases, Kobe University Hospital, Kobe, Japan, ³The Center for Rheumatic Diseases,, Kobe University Hospital, Kobe, Japan, ⁴The Center for Rheumatic Diseases, Kobe University Hospital / Departmant of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, ⁵Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: The mammalian clock genes including Clock (circadian locomotor output cycles kaput), Bmal1 (brain and muscle Arnt-like protein 1), Per (Period) and Cry (Cryptochrome) regulate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].